SeaBeLife Biotech

📍 Roscoff, France🗓 Founded 2019👥 15 employees💰 Last funded Apr 2025
Biotechnology Research🌐 seabelife.com
Website LinkedIn
We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.
6
Total investors
4
Early stage
1
Mid stage
1
Late stage
2019
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
6
Investor activity2020–2025 · investors recorded per year
202042023120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in SeaBeLife Biotech?
SeaBeLife Biotech has 6 investors on record on gritt.io, including 4 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did SeaBeLife Biotech last raise funding?
The most recent investment in SeaBeLife Biotech recorded on gritt.io was in April 2025.
When was SeaBeLife Biotech founded?
SeaBeLife Biotech was founded in 2019.
What industry is SeaBeLife Biotech in?
SeaBeLife Biotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SeaBeLife Biotech based?
SeaBeLife Biotech is headquartered in Roscoff, France.